C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 1, 2013, Pages 33-36

  Farne, Hugo A ^a   Martin, Natasha K ^c   Main, Janice ^b   Orchard, Timothy ^b   Tyrrell Price, Jonathan ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

C reactive protein; Clostridium difficile; Metronidazole; Vancomycin

Indexed keywords

C REACTIVE PROTEIN; CREATININE; METRONIDAZOLE; VANCOMYCIN;

ADULT; AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CREATININE; DRUG SUBSTITUTION; FEMALE; HUMANS; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; METRONIDAZOLE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE; VANCOMYCIN;

EID: 84870911657     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328359ed6c     Document Type: Article

References (17)

1. McFarland LV. Antibiotic-associated diarrhoea: epidemiology, trends and treatment. Future Microbiol 2008; 3:563-578.
2. Bartlett JG. Narrative review: the new epidemic of Clostridium difficileassociated enteric disease. Ann Intern Med 2006; 145:758-764.
3. Mayor S. Battle against hospital acquired infections has been too limited, MPs' report says. BMJ 2009; 339:b4680.
4. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-353.
5. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhea and colitis. Lancet 1983; 2:1043-1046.
6. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-307.
7. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992; 117:297-302.
8. Department of Health and Health Protection Agency. Clostridium difficile infection: how to deal with the problem. December 2008. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-093220 [Accessed 24 August 2012].
9. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald C, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455.
10. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004; 38:414-418.
11. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007; 55:495-501.
12. Pépin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-472.
13. Bhangu S, Bhangu A, Nightingale P, Michael A. Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea. Colorectal Dis 2010; 12:241-246.
14. Hardt C, Berns T, Treder W, Dumoulin FL. Univariate and multivariate analysis of risk factors for severe Clostridium difficile-associated diarrhoea: importance of co-morbidity and serum C-reactive protein. World J Gastroenterol 2008; 14:4338-4341.
15. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905-910.
16. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47:56-62.
17. Gujja D, Friedenberg FK. Predictors of serious complications due to Clostridium difficile infection. Aliment Pharmacol Ther 2009; 29:635-642.